Copyright Reports & Markets. All rights reserved.

Global Drugs for Treating Hyperuricemia Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Drugs for Treating Hyperuricemia Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Uric Acid Production Inhibitors
    • 1.3.3 Urate-stimulating Excretion Agents
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Drugs for Treating Hyperuricemia Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals and Clinics
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Drugs for Treating Hyperuricemia Market Size & Forecast
    • 1.5.1 Global Drugs for Treating Hyperuricemia Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Drugs for Treating Hyperuricemia Sales Quantity (2021-2032)
    • 1.5.3 Global Drugs for Treating Hyperuricemia Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Teva
    • 2.1.1 Teva Details
    • 2.1.2 Teva Major Business
    • 2.1.3 Teva Drugs for Treating Hyperuricemia Product and Services
    • 2.1.4 Teva Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Teva Recent Developments/Updates
  • 2.2 Mylan Pharmaceuticals
    • 2.2.1 Mylan Pharmaceuticals Details
    • 2.2.2 Mylan Pharmaceuticals Major Business
    • 2.2.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product and Services
    • 2.2.4 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Mylan Pharmaceuticals Recent Developments/Updates
  • 2.3 Takeda Pharmaceuticals
    • 2.3.1 Takeda Pharmaceuticals Details
    • 2.3.2 Takeda Pharmaceuticals Major Business
    • 2.3.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product and Services
    • 2.3.4 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Takeda Pharmaceuticals Recent Developments/Updates
  • 2.4 Sanwa Kagaku Kenkyusho
    • 2.4.1 Sanwa Kagaku Kenkyusho Details
    • 2.4.2 Sanwa Kagaku Kenkyusho Major Business
    • 2.4.3 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product and Services
    • 2.4.4 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
  • 2.5 Towa Pharmaceutical
    • 2.5.1 Towa Pharmaceutical Details
    • 2.5.2 Towa Pharmaceutical Major Business
    • 2.5.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product and Services
    • 2.5.4 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Towa Pharmaceutical Recent Developments/Updates
  • 2.6 Toa Eiyo
    • 2.6.1 Toa Eiyo Details
    • 2.6.2 Toa Eiyo Major Business
    • 2.6.3 Toa Eiyo Drugs for Treating Hyperuricemia Product and Services
    • 2.6.4 Toa Eiyo Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Toa Eiyo Recent Developments/Updates
  • 2.7 AstraZeneca
    • 2.7.1 AstraZeneca Details
    • 2.7.2 AstraZeneca Major Business
    • 2.7.3 AstraZeneca Drugs for Treating Hyperuricemia Product and Services
    • 2.7.4 AstraZeneca Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 AstraZeneca Recent Developments/Updates
  • 2.8 Mochida Pharmaceutical
    • 2.8.1 Mochida Pharmaceutical Details
    • 2.8.2 Mochida Pharmaceutical Major Business
    • 2.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product and Services
    • 2.8.4 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Mochida Pharmaceutical Recent Developments/Updates
  • 2.9 Lannett Company
    • 2.9.1 Lannett Company Details
    • 2.9.2 Lannett Company Major Business
    • 2.9.3 Lannett Company Drugs for Treating Hyperuricemia Product and Services
    • 2.9.4 Lannett Company Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Lannett Company Recent Developments/Updates
  • 2.10 Horizo​​n Therapeutics
    • 2.10.1 Horizo​​n Therapeutics Details
    • 2.10.2 Horizo​​n Therapeutics Major Business
    • 2.10.3 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product and Services
    • 2.10.4 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Horizo​​n Therapeutics Recent Developments/Updates
  • 2.11 Sanofi
    • 2.11.1 Sanofi Details
    • 2.11.2 Sanofi Major Business
    • 2.11.3 Sanofi Drugs for Treating Hyperuricemia Product and Services
    • 2.11.4 Sanofi Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Sanofi Recent Developments/Updates
  • 2.12 GSK
    • 2.12.1 GSK Details
    • 2.12.2 GSK Major Business
    • 2.12.3 GSK Drugs for Treating Hyperuricemia Product and Services
    • 2.12.4 GSK Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 GSK Recent Developments/Updates
  • 2.13 Fuji Yakuhin
    • 2.13.1 Fuji Yakuhin Details
    • 2.13.2 Fuji Yakuhin Major Business
    • 2.13.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Product and Services
    • 2.13.4 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Fuji Yakuhin Recent Developments/Updates

3 Competitive Environment: Drugs for Treating Hyperuricemia by Manufacturer

  • 3.1 Global Drugs for Treating Hyperuricemia Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Drugs for Treating Hyperuricemia Revenue by Manufacturer (2021-2026)
  • 3.3 Global Drugs for Treating Hyperuricemia Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Drugs for Treating Hyperuricemia by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Drugs for Treating Hyperuricemia Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Drugs for Treating Hyperuricemia Manufacturer Market Share in 2025
  • 3.5 Drugs for Treating Hyperuricemia Market: Overall Company Footprint Analysis
    • 3.5.1 Drugs for Treating Hyperuricemia Market: Region Footprint
    • 3.5.2 Drugs for Treating Hyperuricemia Market: Company Product Type Footprint
    • 3.5.3 Drugs for Treating Hyperuricemia Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Drugs for Treating Hyperuricemia Market Size by Region
    • 4.1.1 Global Drugs for Treating Hyperuricemia Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Drugs for Treating Hyperuricemia Consumption Value by Region (2021-2032)
    • 4.1.3 Global Drugs for Treating Hyperuricemia Average Price by Region (2021-2032)
  • 4.2 North America Drugs for Treating Hyperuricemia Consumption Value (2021-2032)
  • 4.3 Europe Drugs for Treating Hyperuricemia Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Drugs for Treating Hyperuricemia Consumption Value (2021-2032)
  • 4.5 South America Drugs for Treating Hyperuricemia Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Drugs for Treating Hyperuricemia Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 5.2 Global Drugs for Treating Hyperuricemia Consumption Value by Type (2021-2032)
  • 5.3 Global Drugs for Treating Hyperuricemia Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 6.2 Global Drugs for Treating Hyperuricemia Consumption Value by Application (2021-2032)
  • 6.3 Global Drugs for Treating Hyperuricemia Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 7.2 North America Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 7.3 North America Drugs for Treating Hyperuricemia Market Size by Country
    • 7.3.1 North America Drugs for Treating Hyperuricemia Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Drugs for Treating Hyperuricemia Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 8.2 Europe Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 8.3 Europe Drugs for Treating Hyperuricemia Market Size by Country
    • 8.3.1 Europe Drugs for Treating Hyperuricemia Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Drugs for Treating Hyperuricemia Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Drugs for Treating Hyperuricemia Market Size by Region
    • 9.3.1 Asia-Pacific Drugs for Treating Hyperuricemia Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Drugs for Treating Hyperuricemia Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 10.2 South America Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 10.3 South America Drugs for Treating Hyperuricemia Market Size by Country
    • 10.3.1 South America Drugs for Treating Hyperuricemia Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Drugs for Treating Hyperuricemia Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Drugs for Treating Hyperuricemia Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Drugs for Treating Hyperuricemia Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Drugs for Treating Hyperuricemia Market Size by Country
    • 11.3.1 Middle East & Africa Drugs for Treating Hyperuricemia Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Drugs for Treating Hyperuricemia Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Drugs for Treating Hyperuricemia Market Drivers
  • 12.2 Drugs for Treating Hyperuricemia Market Restraints
  • 12.3 Drugs for Treating Hyperuricemia Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Drugs for Treating Hyperuricemia and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Drugs for Treating Hyperuricemia
  • 13.3 Drugs for Treating Hyperuricemia Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Drugs for Treating Hyperuricemia Typical Distributors
  • 14.3 Drugs for Treating Hyperuricemia Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Drugs for Treating Hyperuricemia market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Drugs used to treat hyperuricemia,a condition characterized by elevated levels of uric acid in the blood,primarily aim to lower uric acid levels to prevent complications such as gout and kidney stones.The most common medications include xanthine oxidase inhibitors like allopurinol and febuxostat,which reduce uric acid production by inhibiting the enzyme responsible for its formation.Another class,uricosuric agents such as probenecid,work by increasing uric acid excretion through the kidneys.
    This report is a detailed and comprehensive analysis for global Drugs for Treating Hyperuricemia market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Drugs for Treating Hyperuricemia market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for Treating Hyperuricemia market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for Treating Hyperuricemia market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Drugs for Treating Hyperuricemia market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Drugs for Treating Hyperuricemia
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Drugs for Treating Hyperuricemia market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Drugs for Treating Hyperuricemia market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Uric Acid Production Inhibitors
    Urate-stimulating Excretion Agents
    Other
    Market segment by Application
    Hospitals and Clinics
    Retail Pharmacies
    Other
    Major players covered
    Teva
    Mylan Pharmaceuticals
    Takeda Pharmaceuticals
    Sanwa Kagaku Kenkyusho
    Towa Pharmaceutical
    Toa Eiyo
    AstraZeneca
    Mochida Pharmaceutical
    Lannett Company
    Horizo​​n Therapeutics
    Sanofi
    GSK
    Fuji Yakuhin
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Drugs for Treating Hyperuricemia product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Drugs for Treating Hyperuricemia, with price, sales quantity, revenue, and global market share of Drugs for Treating Hyperuricemia from 2021 to 2026.
    Chapter 3, the Drugs for Treating Hyperuricemia competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Drugs for Treating Hyperuricemia breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for Treating Hyperuricemia market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for Treating Hyperuricemia.
    Chapter 14 and 15, to describe Drugs for Treating Hyperuricemia sales channel, distributors, customers, research findings and conclusion.

    Buy now